On April 23, 2025, MIRA Pharmaceuticals announced that their new topical drug, Ketamir-2, successfully passed laboratory tests for drug release, marking a significant milestone towards clinical trials and expanding treatment options for pain relief. The U.S. topical pain relief market is projected to exceed $11.5 billion in 2025, positioning MIRA strategically within this growing market.